JCSE01.17 Weekly Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy for IIIA-N2 Lung Squamous Cell Carcinoma: A Prospective Phase II Study

Y. Zhang; J.Q. Zhu; D. Yue; X. Zhao; Q. Zhang; H. Chen; C. Wang

首页> 外文期刊>Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer >JCSE01.17 Weekly Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy for IIIA-N2 Lung Squamous Cell Carcinoma: A Prospective Phase II Study

【24h】

JCSE01.17 Weekly Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy for IIIA-N2 Lung Squamous Cell Carcinoma: A Prospective Phase II Study

机译：JCSE01.17每周NAB-PACLITAXEL PLUS Carboplatin作为IIIA-N2肺鳞状细胞癌的Neoadjuvant疗法：一项潜在的II研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer》 |2018年第10期|共1页
作者
Y. Zhang; J.Q. Zhu; D. Yue; X. Zhao; Q. Zhang; H. Chen; C. Wang;
展开▼
作者单位

Tianjin Medical University Cancer Institute and Hospital;

Tianjin Medical University Cancer Institute and Hospital;

Tianjin Medical University Cancer Institute and Hospital;

Tianjin Medical University Cancer Institute and Hospital;

Tianjin Medical University Cancer Institute and Hospital;

Tianjin Medical University Cancer Institute and Hospital;

Tianjin Medical University Cancer Institute and Hospital;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. JCSE01.17 Weekly Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy for IIIA-N2 Lung Squamous Cell Carcinoma: A Prospective Phase II Study [J] . Y. Zhang, J.Q. Zhu, D. Yue, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2018,第10期

机译：JCSE01.17每周NAB-PACLITAXEL PLUS Carboplatin作为IIIA-N2肺鳞状细胞癌的Neoadjuvant疗法：一项潜在的II研究
2. A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002) [J] . Wang Zhen, Huang Cheng, Yang Jin-Ji, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2019,第期

机译：与吉西他滨和卡铂的随机期II临床试验与吉西他滨和卡铂作为先进鳞状细胞肺癌的一线治疗（C-TONG1002）
3. Phase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III-IVB head and neck squamous cell carcinoma (HNSCC) [J] . FuryM.G., ShermanE.J., RaoS.S., Annals of oncology: official journal of the European Society for Medical Oncology . 2014,第3期

机译：III期IVB期头颈部鳞状细胞癌（HNSCC）患者每周一次纳布紫杉醇+西妥昔单抗+调强放射治疗（IMRT）的I期研究
4. CCND1 as a Predictive Biomarker of Neoadjuvant Chemotherapy in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma [C] . Zhien Feng, Lizhen Wang, Bingshun Wang, Academic Committee Conference of Shanghai key lab of stomatology . 2011

机译：CCND1作为局部晚期头颈部鳞状细胞癌患者新辅助化疗的预测生物标志物
5. Gene expression analysis of human non -small cell lung cancer subtypes, adenocarcinoma and squamous cell carcinoma, and mouse lung epithelial cell lines: Implications in lung tumorigenesis [D] . Silvers, Amy Lynn. 2002

机译：人类非小细胞肺癌亚型，腺癌和鳞状细胞癌以及小鼠肺上皮细胞系的基因表达分析：在肺肿瘤发生中的意义
6. Phase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III–IVB head and neck squamous cell carcinoma (HNSCC) [O] . M. G. Fury, E. J. Sherman, S. S. Rao, -1

机译：I期研究–每周一次纳布紫杉醇+每周西妥昔单抗+调强放射治疗（IMRT）在III–IVB期头颈部鳞状细胞癌（HNSCC）患者中
7. JCSE01.17 Weekly Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy for IIIA-N2 Lung Squamous Cell Carcinoma: A Prospective Phase II Study [O] . Y. Zhang, J.Q. Zhu, D. Yue, 2018

机译：JCSE01.17每周NAB-PACLITAXEL PLUS Carboplatin作为IIIA-N2肺鳞状细胞癌的Neoadjuvant疗法：一项潜在的II研究

JCSE01.17 Weekly Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy for IIIA-N2 Lung Squamous Cell Carcinoma: A Prospective Phase II Study

著录项

相似文献

相关主题

期刊订阅